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ABSTRACT
Objective. Vitamin D status influences 
the risk to develop autoimmune dis-
eases affecting the percentage and/or 
functions of regulatory T cells (Tregs). 
Since low levels of 25 (OH) D have 
been decreased in patients with system-
ic sclerosis (SSc), we aimed to study the 
effect of Vitamin D3 (cholecalciferol) 
supplementation on Tregs frequencies 
and functions.
Methods. Peripheral blood and sera 
samples were obtained from 45 SSc pa-
tients and controls (HC). A number of 
eighteen SSc patients had consumed 
Cholecalciferol (orally) at the dose of 
25.000 UI/month for 6 months at the 
time of enrollment. 25(OH)D serum lev-
els were measured and VDR polymor-
phisms, were genotyped by polymerase 
chain reaction (PCR). Tregs isolated 
from peripheral blood mononuclear cells 
were in vitro expanded and a suppression 
assay was performed. Flow cytometry 
analysis was then carried out. Finally, 
IL-10 production was assayed by ELISA.
Results. Low serum levels of 25(OH)D 
were detected in SSc patients. The per-
centage of Tregs in SSc patients was sim-
ilar to controls, but, among SSc patients, 
it was higher in those patients taking 
cholecalciferol. Tregs capability to sup-
press T cell proliferation was impaired 
in SSc patients and not restored after in 
vitro pre-treatment with the active form 
of Vitamin D (1,25(OH)2D3); but at the 
same time the production of IL-10 was 
increased in treated samples obtained 
from patients. The lack of response of 
Tregs from SSc patients to 1,25(OH)2D3 
treatment in vitro was not due to altered 
Vitamin D/VDR signalling. 
Conclusion. Altogether, our results in-
dicate that the increased production of 
IL-10 by 1,25(OH)2D3 -treated Tregs 
could provide a “suppressive” cytokine 
milieu able to modulate immune re-
sponse but it is not sufficient to restore 
the immune suppressive functions of 
Tregs.
Introduction
Systemic sclerosis (SSc) is an autoim-
mune disorder characterised by tissue 
fibrosis of several organs, including the 
skin. SSc can be classified in two main 
subtypes, the limited cutaneous form 
(lcSSc) and the diffuse cutaneous form 
(dcSSc), according to the skin fibrosis 
extension (1).
Skin fibrosis, together with reduced sun 
exposure may be considered a possi-
ble cause of hypovitaminosis D, which 
is commonly observed in SSc patients 
and in patients with several autoimmune 
conditions, including rheumatoid arthri-
tis (RA), systemic lupus erythematosus 
(SLE) and undifferentiated connective 
tissue diseases (UCTD) (2, 3).
However, the role of vitamin D status 
in the pathogenesis of SSC is not fully 
investigated (4-6).
The active form of Vitamin D 
(1,25(OH)2D3) activates the vitamin D 
receptor (VDR), a member of the super-
family of nuclear receptors, recognised 
as a key regulator of calcium homeo-
stasis cell proliferation, differentiation 
and immunomodulation (7, 8). Upon 
binding to VDR, the 1,25(OH)2D3 
stimulates regulatory T cells, which is 
a central player in the maintenance of 
peripheral self-tolerance (9).
In vitro treatment of T cells from 
healthy individuals with TX527, a 
low-calcemic analogue of bioac-
tive 1,25(OH)2D3, can promote a 
CD4+CD25highCD127low regulatory 
(Treg) profile and imprint a migratory 
signature specific for homing to sites of 
inflammation (10, 11). Intriguingly, the 
1,25(OH)2D3-induced Tregs exhibited 
the capacity to suppress proliferation of 
autologous responder T cells.
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In SSc, conflicting data are reported on 
the frequency and functional activity of 
Tregs, but there is a general agreement 
in favour of a decreased functional ca-
pacity of circulating Tregs (12, 13).
The aim of our study was to evaluate the 
effect of a 1,25(OH)2D3 supplementa-
tion on Tregs frequency (%Tregs) and 
functions in SSc patients. We have also 
analysed a possible association between 
VDR polymorphisms and SSc (14).
Material and methods
Patients
The patients enrolled in this study, had 
been diagnosed SSc according to the 
2013 classification criteria for systemic 
sclerosis (15) (inclusion criteria). Pe-
ripheral blood and sera samples were 
obtained following informed consent 
from 45 patients (F:M 41:4) with SSc 
(32 patients with limited and 13 with 
diffuse SSc), and 35 healthy controls 
(HC). Eighteen SSc patients had con-
sumed Cholecalciferol orally, at the dose 
of 25.000 UI/month for 6 months at the 
time of enrollment. Patients with other 
autoimmune disorders were excluded 
from this study (exclusion criteria).
Modified Rodnan skin score was cal-
culated in all patients (mean±SD: dif-
fuse SSc 31±5, limited SSc 12±7). Pul-
monary involvement was defined as a 
forced vital capacity <70% of predict-
ed, as measured by a dry spirometer, or 
by the evidence of amorphous or retic-
ulonodular infiltrates in high resolution 
computed tomography scans (HRCT) 
(7 out of 45 patients showed pulmo-
nary involvement). Pulmonary arterial 
hypertension (PAH) was evaluated in-
directly by Doppler echocardiography, 
according to Denton et al. and then 
confirmed by Right heart catheterisa-
tion (2 out of 45 patients showed PAH) 
(16). Autoantibodies profiles were also 
evaluated and all the patients were 
ANA+ (27 SSc patients were also posi-
tive for Scl70 and 2 for CENPB) (ANA 
in indirect immunofluorescence and 
ENA in immunoblot assay). Patients’ 
characteristics are shown in Table I. 
This study was approved by the ethical 
committee of the University Hospital 
Policlinico Paolo Giaccone in Palermo, 
Italy; and informed consent was ob-
tained from each patient and controls.
25(OH)D measurements
25(OH)D serum levels were measured 
on frozen samples (-70°C) with the Ar-
chitect i1000SR (Abbott Laboratories, 
Wiesbaden, Germany), according to 
the manufacturer’s instructions. 
Genetic analysis
Genomic DNA was extracted from 200 
μl of whole peripheral blood using a 
commercial Kit (Qiagen, Valencia, 
CA, USA) according to the manufac-
turer’s instructions. The DNA quality 
was evaluated by electrophoresis in a 
0.8% agarose gel, quantified by using 
absorbance spectrophotometric analy-
sis and stored at -20°C for subsequent 
analysis.
The VDR polymorphisms, Fok-I, 
Bsm-I, Taq-I and Apa-I, were geno-
typed by polymerase chain reaction 
(PCR) followed by restriction frag-
ment length polymorphism (RFLP) 
analysis. Primers for VDR gene poly-





TTCGTAG-3´ and reverse 5´- ATAG-
GCAGAACCATCTCTCAG-3´; Apa-I 
forward 5´- CAGAGCATGGAC-
AGGGAGCAAG-3´ and reverse 
5´-GCAACTCCTCATGGCTGAG-
GTCTCA-3´; Taq-I forward 5´-CA-
GAGCATGGACAGGGAGCAAG-3´ 
and reverse 5´-GCAACTCCTCATG-
GCTGAGGTCTCA-3´. The following 
conditions were used for both Fok-I 
and Bsm-I amplification: 94°C for 5´, 
35 cycles of 94°C for 1´, 60°C for 1’ 
and 72°C for 1´, followed by 72°C for 
10´. The PCR products were separately 
restricted in a 25 μl reaction volume for 
2 h with Fok-I at 55°C and Bsm-I at 
37°C, respectively.
Fok-I and Bsm-I genotyping was made 
as follows FF:272 bp, Ff: 272, 191 and 
81 bp, ff: 191 and 81 bp; BB:191 bp, 
Bb: 191,115 and 76 bp, bb: 115 and 76 
bp, respectively.
The amplification for Apa-I and Taq-I 
was performed according to the fol-
lowing program: 93°C for 10 min and 
35 cycles of 93°C for 45 s, 66°C for 30 
s, 72°C for 45 s, followed by 72°C for 
10 min. PCR products were digested 
for 2 h with APA I at 25°C and TAQ I 
at 65°C, respectively. Apa-I and Taq-I 
digestion revealed genotypes denoted, 
respectively, as AA (740 bp), aa (520 
and 220 bp) and Aa (740, 520 and 220 
bp) and TT (245 and 495 bp), tt (290, 
245 and 205 bp) and Tt (495, 290, 245 
and 205 bp).
All PCR products were separated by 
electrophoresis on a 2% agarose gel 
stained with Eurosafe (Euroclone).
Approximately, 20% of the samples 
were randomly selected and genotyped 
in duplicate and 20% of the samples 
were confirmed by DNA sequencing. 
All results were concordant.
Tregs expansion, suppression assay 
and flow cytometry
PBMCs were isolated by lymphocyte 
(PAA, Austria) density gradient cen-
trifugation. CD4+CD25+ T cells were 
purified by negative selection of CD4+ 
T cells followed by positive selection 
of CD25+ T cells using miniMACS 
CD4+CD25+ T Regulatory Cell Isola-
tion Kit (Miltenyi-Biotec, UK). The pu-
rity of CD4+CD25+ T cells was between 
90-98%. Aliquots of CD4+CD25− T 
cells (effector T cells, Teff) were cryo-
preserved and used as autologous re-
Table I. Main demographic, clinical and laboratory features of patients enrolled at baseline.
Patients’ features Whole series n= 45
Sex, female, n (%) 41  (91.1)
Age, years mean (SD) 58 ± 14
Disease duration from first non-Raynaud sign/symptom, years median (range) 12  (2–40)
lcSSc, n (%) 32  (71.1)
Pulmonary involvement(%) 7  (15.5)
Pulmonary arterial hypertension (%)   2  (4.4)
ANA   43  (95.5)
Anti-Scl70   18  (40)
SD: standard deviation; lcSSc: limited cutaneous disease.
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sponder cells in suppression assays 
after staining with carboxyfluorescein 
succinimidyl ester (CFSE, eBiosci-
ence, San Diego, CA, USA). Human 
CD4+CD25+T cells were plated at 
1×106/mL in X-Vivo15 (Lonza), con-
taining Rapamycin (100nM; LC-Lab-
oratories). Cells were activated with 
anti-CD3/CD28 beads (ratio bead:cell 
of 1:2; Invitrogen, UK). IL-2 (1000 IU/
mL; Proleukin-Novartis) was added at 
day 4 post activation and replenished 
every two days. Cells were re-stimulat-
ed every 10-12 days, and used after 36 
days from the first activation (3 rounds 
of stimulation). Cells were also cul-
tured in presence of 1,25(OH)2D3 (10-
8M) (Roche) for the suppression assays.
As for the characterisation of Tregs, 
the cells were stained with the follow-
ing antibodies: anti-human CD3 FITC 
conjugated, clone HIT3a, (eBiosci-
ence Affymetrix INC San Diego, CA, 
USA), anti-human CD25 PE conju-
gated (Miltenyi, Biotec), anti-human 
CD4 PE-Cy7 conjugated, clone OKT4, 
(BioLegend, San Diego, CA, USA), 
anti-human FoxP3 APC, clone 259D 
(BioLegend) and an anti-human CD45 
APC/Cy7 conjugated, clone HI30, 
(BioLegend). For the exclusion of dead 
cells, a 7-AAD cell viability staining 
solution was used. 
Flow cytometry analysis was performed 
by using a fluorescence activated cell 
sorter (FACS)Canto (BD Biosciences, 
San Jose, CA, USA). At least 50.000 
cells (events), gated on the lymphocyte 
region, were acquired for each sample 
and data are presented as a percentage 
of total alive cells in the CD45 channel.
Enzyme-linked immunosorbent assay 
(ELISA) for IL-10
IL-10 production from cell culture su-
pernatant was assayed by commercial 
ELISA (Abcam, Cambridge, UK).
Statistical analysis
Parametric and non-parametric statisti-
cal analysis was performed by calcu-
lating the mean ± standard error of the 
mean (s.e.m.) and median, respectively. 
For comparison of parametric and non-
parametric data, the t-test and Mann-
Whitney rank-sum test were used 
where appropriate. Spearman’s corre-
lation analysis was utilised to quantify 
the expression associations between 
the genes of interest. p-values less than 
0.05 were considered to be significant. 
The statistical analysis was performed 
by using GraphPAd software. 
Results
Impaired suppressive capability 
of Tregs in SSc
The mean percentage of CD4+CD25+ 
FOXP3+ Treg cells in SSc patients 
(2.9±0.2) was not different from the 
control group (3.1±0.52) and data from 
two groups were not statistically signif-
icant (Fig. 1 A-D). No differences were 
found in patients with PAH and lung 
involvement (data not shown). In order 
to evaluate the ability of Tregs from pa-
tients and controls to suppress effector 
cells, purified CD4+CD25+ T cells (Fig. 
Fig. 1. Representative gating strategy of lymphocytes in SSc patients and controls.
(A) Dot plot panels showing mean percentages of Tregs of (B) SSc patients and (C) controls. (D) Histogram showing CD4+ CD25+ FOXP3+ cells per-
centages detected in healthy controls and SSc patients. (E) Dot plot representing purified CD4+CD25+ cells. (F) Representatives histograms of suppression 
assays of Tregs from SSc patients and healthy controls.
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1E), obtained after 3 rounds of stimu-
lation, were activated with anti-CD3/
CD28 beads to perform the suppression 
assay. Tregs from HC nicely suppressed 
proliferation of autologous CD4 T cells, 
but Tregs from SSc patients failed to 
suppress CD4 T cell proliferation (Fig. 
1F). This indicates that Tregs activity is 
functionally impaired in SSc patients. 
Tregs from SSc patients assuming 
vitamin D are increased in percentages, 
fail to suppress T cell proliferation 
but secrete more IL-10
Taking into account the important role 
of vitamin D in the modulation of Treg 
functions and the reduced 25(OH)
D serum level found in SSc patients 
(median 22.1±9.7 μg/l, n=45) (Fig. 
2A), we evaluated whether treatment 
with 1,25(OH)2D3 in vitro was able 
to increase the Tregs percentages. As 
shown in Figure 2B-C, the percent-
ages of Tregs in patients treated with 
Vitamin D were significantly increased 
when compared to percentages of Tregs 
of SSc patients. The suppression as-
say was performed with Tregs that 
had been cultured for five days with 
1,25(OH)2D3, or with untreated Tregs 
from SSc patients.  As shown in Figure 
2D, 1,25(OH)2D3-pretreated Tregs still 
failed to suppress effector cell prolifer-
ation. Furthermore, Tregs from SSc pa-
tients who were taking cholecalciferol 
orally, even if expanded (Fig. 2B) were 
not able to suppress effector cells pro-
liferation (Treg/Teff 1:3 92.1%, mean 
percentage of proliferating effector 
cells). On the contrary, healthy subjects 
maintained the suppressive ability also 
when pretreated with 1,25(OH)2D3 
(Treg/Teff 1:3 32.3%, mean percentage 
of proliferating effector cells).
The lack of response of Tregs from SSc 
patients after in vitro treatment was not 
due to altered Vitamin D/VDR signal-
ling. The analysis of VDR polymor-
phisms did not reveal significant differ-
ences in genotypic and allelic frequen-
cies among the analysed SSc patients 
and controls (Fig. 2E). 
However, despite the treatment with 
1,25(OH)2D3 failed to restore the 
suppressive capability of Tregs, it de-
termined a statistically significant 
increase of IL-10 production in the 
supernatant of treated Tregs, when 
compared to IL-10 secreted by un-
treated Tregs (Fig. 2F), thus suggest-
ing a possible immunomodulatory 
function of 1,25(OH)2D3.  Moreover, 
1,25(OH)2D3 directly correlate with 
Tregs percentage (Fig. 2G).
Discussion
The reduced numbers, percentages 
and/or functions of Tregs (mostly 
CD4+CD25+FOXP3+) have been re-
ported in many autoimmune diseases 
(17). In SSc a big debate still exists on 
the role of Tregs in the pathogenesis of 
the disease and the data reported are 
controversial. Radstalk and Slobodin 
(18, 19) found increased numbers of 
Tregs with defective suppressive ac-
tivities in the peripheral blood of SSc 
patients. On the contrary, Fenoglio et 
Fig. 2. (A) 25(OH)D serum levels in SSc patients and controls. (B) Histograms representing percentages of CD4+CD25+FOXP3+ cells obtained from SSc 
assuming cholecalciferol. (C) Histogram showing suppression activity of in vitro VitD3 Tregs from SSc patients. (D) Histogram showing suppression activ-
ity displayed by Vitamin D3 in vitro-treated Tregs of SSc patients. (E) Distribution of genotype frequencies of the VDR gene polymorphisms in SSc and 
control group. (F) IL-10 levels (pg/ml) in the supernatant of Vitamin D3 in vitro-treated Tregs.
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al. (20) described decreased frequen-
cies of Tregs in SSc patients. In line 
with other studies, (21) in which the 
percentages of Tregs did not differ 
between patients and control subjects, 
our study shows that Tregs percentages 
were similar in SSc patients and in con-
trols, but interestingly, the suppressive 
function of Tregs from SSc patients 
was abrogated. 
It is possible to speculate that periph-
eral blood Tregs are not able to over-
come the inflammatory response chal-
lenged by Th1/Th17 cells and/or their 
cytokines, as demonstrated in many 
systemic autoimmune diseases. Re-
sistance of T effector cells to Tregs 
has been described in experimental 
models of SLE (22), multiple sclerosis 
(MS) and diabetes (23-27), and might 
be due to an overwhelming inflamma-
tory response. For this reason, in our 
model, the use of cholecalciferol could 
be considered a therapeutic strategy to 
modify the inflammatory state, given 
its ability to increase IL-10 production. 
Vitamin D status modulates immune 
response by different mechanisms 
(28), amongst which is the activation 
of a subset of Tregs expressing IL10 or 
FOXP3 (29). We speculate that, in our 
model, 1,25(OH)2D3 could enhance 
IL10 production and may in turn sup-
press FOXP3 expression inhibiting 
their suppressive functions. This mech-
anism could explain the reason why 
1,25(OH)2D3-treated Tregs in SSc pa-
tients do not suppress polyclonal pro-
liferation of effector T lymphocytes.
According to our data, different au-
thors (30,31) have described low levels 
of 25(OH)D in SSc patients and several 
trials have been conducted using chole-
calciferol as a therapeutic agent in dif-
ferent diseases such as MS, RA, SLE, 
Crohn’s disease and type I diabetes. 
The clinical benefit of cholecalciferol 
supplementation in autoimmunity was 
explained by different mechanisms, 
including upregulation of suppressive 
functions. Even if we detected a fail-
ure of suppression of T effector cells by 
Tregs in vitro exposed to 1,25(OH)2D3 
in SSc patients, we found a significant-
ly increased production of IL-10.
Finally, different results from the liter-
ature assigned an unclear role to vari-
ants of VDR in the pathogenesis of au-
toimmune diseases (28). In our study, 
however, the inability of 1,25(OH)2D3 
to restore the suppressive potential of 
Tregs was not correlated to a specific 
polymorphic variant of VDR because 
there was no difference in the genomic 
polymorphic variants expressed by SSc 
patients and healthy controls.
Conclusions
Altogether, our data suggest that 
1,25(OH)2D3 can induce an increase 
of IL-10 secretion by Tregs from SSc 
patients, but their inability to suppress 
T cell proliferation doesn’t change with 
this treatment. In order to better define 
the pathogenesis of diseases, a deeper 
analysis is needed of IL10+ Tregs at 
the site of the disease, the correlation 
between IL-10+ cells and FOXP3+ cells 
in the damaged tissues and a possible 
resistance to Tregs of T effector cells 
from SSc patients.
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